Reviewing the cost effectiveness of rotavirus vaccination: The importance of uncertainty in the choice of data sources

PharmacoEconomics

Volumn 27, Issue 4, 2009, Pages 281-297

  Bilcke, Joke ^a   Beutels, Philippe ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

AMBULATORY CARE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; METHODOLOGY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; VACCINATION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

COST-BENEFIT ANALYSIS; DATA COLLECTION; HUMANS; MODELS, ECONOMIC; RESEARCH SUPPORT AS TOPIC; ROTAVIRUS VACCINES; UNCERTAINTY;

EID: 67649858504     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927040-00002     Document Type: Review

References (45)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9 (5): 565-72
2. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344 (8): 564-72
3. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10 (8): 751-74
4. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434-46
5. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13-38
6. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002-2006). Vaccine 2007; 25 (8): 1355-67
7. Drummond M, O'Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
8. Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
9. Beutels P, Scuffham P, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect D 2008; 8 (11): 727-33
10. Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 8-15; discussion 23-5
11. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
12. Tebbens RJD, Thompson KM, Hunink MGM, et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Med Decis Making 2008; 28 (2): 182-200
13. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregivers' burden and "no medical care" disease impact in Belgium. Med Decis Making. Epub 2008 Oct 23
14. Takala AK, Koskenniemi E, Joensuu J, et al. Economic evaluation of rotavirus vaccinations in Finland: random- ized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998; 27 (2): 272-82
15. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000; 9 (1): 19-35
16. Puliyel JM. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B, Streptococcus pneumoniae -conjugate and Rotavirus vaccines in the national immunization schedules [author reply]. Health Econ 2004; 13 (11): 1147-8
17. Podewils LJ, Antil L, Hummelman E, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192 Suppl. 1: S133-45
18. Carlin JB, Jackson T, Lane L, et al. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999; 23 (6): 611-6
19. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25 (52): 8851-60
20. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26 (5): 706-15
21. Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93 (1): 52-8
22. Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26 (8): 1118-27
23. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25 (20): 3971-9
24. Lorgelly PK, Joshi D, Iturriza Gomara M, et al. Exploring the cost-effectiveness of an immunisation programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2007; 136 (1): 44-55
25. Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995; 96 (4 Pt 1): 609-15
26. Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998; 279 (17): 1371-6
27. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119 (4): 684-97
28. Rheingans RD, Constenla D, Antil L, et al. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 205-16
29. de Soárez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23 (4): 221-30
30. Constenla D, O'Ryan M, Navarrete MS, et al. Potential cost effectiveness of a rotavirus vaccine in Chile. Rev Med Chil 2006; 134 (6): 679-88
31. Constenla D, Ortega-Barria E, Rheingans RD, et al. Economic impact of rotavirus vaccination in Panama. An Pediatr (Barc) 2008; 68 (2): 128-35
32. Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25 (2): 373-80
33. Constenla D, Perez-Schael I, Rheingans RD, et al. Assessment of the economic impact of the antiretroviral vaccine in Venezuela. Rev Panam Salud Publica 2006; 20 (4): 213-22
34. Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192 (10): 1720-6
35. Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1-7
36. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191-215
37. Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy and Safety Trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354 (1): 23-33
38. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57 (25): 697-700
39. Rheingans RD, Constenla D, Antil L, et al. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 192-204
40. Sartori AM, Valentim J, de Soarez PC, et al. Rotavirus morbidity and mortality in children in Brazil. Rev Panam Salud Publica 2008; 23 (2): 92-100
41. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004; 22 (25-26): 3312-22
42. Coyle D, Lee KM. Evidence-based economic evaluation: how the use of different data sources can impact results. In: Donaldson C, Mugford M, Vale L, editors. Evidencebased health economics: from effectiveness to efficiency in systematic review. London: BMJ Books, 2002: 55-66
43. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
44. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781-98
45. Manning WG, Fryback DG, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 247-75